Navigation Links
New Anticoagulant Pill Works Well in Trial
Date:6/17/2009

Lower doses safe and effective after heart attack and stroke

WEDNESDAY, June 17 (HealthDay News) -- The new anti-clotting pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack and death in patients who have had a heart attack or suffer from unstable angina, a new trial shows.

Rivaroxaban is a pill that blocks factor Xa, which is involved in blood clotting. In earlier studies, the drug was effective in preventing venous thromboembolism (blood clots in the legs) after orthopedic surgery, although some increased risk in bleeding episodes was seen. In this phase II trial, researchers tested the safety and efficacy of the drug at various doses.

"The use of an oral factor Xa inhibitor in patients stabilized after an acute coronary syndrome increases bleeding in a dose-dependent manner, and might reduce major ischemic outcomes," said lead researcher Dr. Jessica L. Mega, from the Cardiovascular Division at Brigham and Women's Hospital in Boston. "On the basis of these observations, a phase III study of low-dose rivaroxaban as adjunctive therapy in these patients is underway."

The report is published in the June 17 online edition of The Lancet.

In March, a U.S. Food and Drug Administration advisory panel voted 15-2 that rivaroxaban, a long-sought alternative to commonly used blood thinners that have to be injected and are tricky to monitor, had benefits that outweighed its bleeding risks. Although the FDA is not bound by the panel's decision, it typically follows suit on these recommendations.

For the study, Mega's group treated 3,491 patients who had had heart attacks or unstable angina with either aspirin or aspirin plus the anti-clotting drug clopidogrel (Plavix).

The patients were then randomly assigned to a placebo or rivaroxaban, at doses ranging from 5 milligrams to 20 milligrams a day. The researchers looked for any significant bleeding and deaths, heart attacks and stroke.

There was an increase in bleeding episodes with rivaroxaban. Over six months, the researchers found that risk increased with dosage. At 5 milligrams, the risk increased 2.2 times, while the 20-milligram dose raised the risk fivefold.

However, patients receiving rivaroxaban had a 21 percent reduction in heart attacks, strokes, ischemic events and deaths compared with patients taking placebo. For heart attack, stroke and death alone, the risk was reduced by 31 percent compared with placebo, the researchers found.

"In this study, rivaroxaban was associated with a dose-dependent increase in clinically significant bleeding events, with a trend towards a reduction in the primary efficacy endpoint of death, myocardial infarction, stroke or severe recurrent ischemia requiring revascularization," Mega and colleagues wrote. "Regarding the main secondary efficacy endpoint, rivaroxaban reduced the rate of death, myocardial infarction or stroke."

Dr. Hitinder S. Gurm, from the University of Michigan Cardiovascular Center and co-author of an accompanying journal editorial, said the study showed no benefit in patients who are using aspirin and Plavix, although there was a suggestion of a benefit when the drug was used with aspirin alone.

"This study was a dose-finding study; it would be premature to assess the future of this drug in patients with acute coronary syndrome based on this trial, and the little bit of data that we have does not suggest the drug would provide a major benefit in patients who are already on contemporary therapy -- with the caveat that we need a larger trial to confirm or refute this," Gurm said.

Dr. Richard C. Becker, director of the Cardiovascular Thrombosis Center at Duke University Medical Center, said this study is another step in the search for an anti-clotting drug to replace warfarin for many patients. Warfarin is an effective drug, but requires constant monitoring to assure that patients are receiving a dose that is not too low, which is ineffective, or too high, which increases the risk of bleeding.

"The trends toward benefit with rivaroxaban, as a fixed-dose, direct and oral factor Xa inhibitor, provide a sound rationale to pursue a path of further investigation," Becker said.

The dose-related bleeding risk supports a strategy of lower doses than would be used for other potential indications for the drug, such as atrial fibrillation and venous thrombosis, he said.

"In the next several years, the field will have a wealth of information on antithrombotic therapies, providing a platform to determine optimal treatment in a wide range of patients with acute coronary syndrome," Becker said.

More information

For more information on anticoagulants, visit the American Heart Association.



SOURCES: Jessica L. Mega, M.D., Cardiovascular Division, Brigham and Women's Hospital, Boston; Hitinder S. Gurm, M.D., director, inpatient services, division of cardiovascular medicine, University of Michigan Cardiovascular Center, Ann Arbor; Richard C. Becker, M.D., director, Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, N.C.; June 17, 2009, The Lancet, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Different anticoagulant regimens yield equal results
2. Comparison of anticoagulants for angioplasty show similar outcomes
3. Anticoagulant Drugs Had Similar Outcomes After Angioplasty
4. Afid Therapeutics Inc.s New Anticoagulant Heparin Replacement Passes in Vivo Test
5. World Anticoagulants Market to Exceed $12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
6. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
7. New MedPredict Report Assesses Current Outlook for Anticoagulants Market
8. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
9. Taxol bristle ball: a wrench in the works for cancer
10. Cancer control in Europe works; now it is time to extend it to poorer countries
11. SecureWorks Ranked 6th in Deloittes Technology Fast 50 Program for Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Anticoagulant Pill Works Well in Trial 
(Date:2/9/2016)... VA (PRWEB) , ... February 09, 2016 , ... ... Small Mammal Prize has officially been won. A team from 21st Century Medicine ... discovered a way to preserve the delicate neural circuits of an intact rabbit ...
(Date:2/8/2016)... D.C. (PRWEB) , ... February 08, 2016 , ... ... officially launched its newly redesigned website, federallabs.org . The site houses a ... or license available federal technologies through the process called technology transfer (T2). As ...
(Date:2/8/2016)... City, GA (PRWEB) , ... February 08, 2016 , ... ... and cavity-free. February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, ... 3 p.m. at Coast Dental , located next to Target at 1207 North ...
(Date:2/8/2016)... Texas (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous for ... members and significant others that they are loved. This year, for more than 5.6 ... they cost - just won't be enough to remind them of the lives they’ve led ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... case packer for pouches, bags, and flow wrapped products at WestPack 2015, February ... specialty product manufacturers step up to semi-automatic or fully-automatic case packing with a ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will promote ... line for long-term implant applications and announce certification ... & Manufacturing (MD&M) West Conference (Booth #1759), February ... --> --> Available in ... LSRs offer outstanding physical properties enabling our customers ...
(Date:2/8/2016)... Respiratory Devices - Medical Devices Pipeline Assessment, 2015 ... " Respiratory Devices - Medical Devices Pipeline Assessment, ... currently in pipeline stage. The report provides ... analysis of the products at various stages of ... the pipeline product development. It also provides information ...
(Date:2/8/2016)... 8, 2016 CBG Technologies, a U.S. ... Solvent Recycling Systems, specifically designed for precision parts ... new and existing vapor degreasers, parts washers and ... through continuous recycling and recovers 100% of the ... --> Precision parts manufacturers benefit from ...
Breaking Medicine Technology: